COVID-19 Phase 1 SAD/MAD FIH Clinical Trial of AV-001
$2,849,345.00
Grant Value
2021-22
Fiscal Year
Description
Vasomune is developing a novel first-in-class investigational medicine to treat patients hospitalized with severe COVID-19 disease. The phase 1 study is the first-in-human study designed to demonstrated safety and tolerability of AV-001 in heathy subjects prior to testing in severely ill patients with COVID-19 disease.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Grant Details
Recipient
Vasomune Therapeutics Inc.
Location
Toronto, ON M5T 1X5
Agreement Details
Number: 965762
Reference: 172-2021-2022-Q2-965762
Timeline
Start: Nov. 1, 2020
End: Dec. 31, 2021
Program
Industrial Research Assistance Program Contributions to Firms
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or …
Sector
Professional, scientific and technical services (541710)
Your Contribution
Calculate how much you personally contributed to this grant through your taxes.
Calculate My Share